[Federal Register Volume 74, Number 119 (Tuesday, June 23, 2009)]
[Notices]
[Page 29718]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-14697]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on May 13, 2009, Austin Pharma 
LLC., 811 Paloma Drive, Suite A, Round Rock, Texas 78665-2402, made 
application by renewal to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of the basic classes of controlled 
substances listed in schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Marihuana (7360)...........................  I
Tetrahydrocannabinols (7370)...............  I
Alphamethadol (9605).......................  I
Nabilone (7379)............................  II
Methadone (9250)...........................  II
Methadone Intermediate (9254)..............  II
Levo-alphacetylmethadol (9648).............  II
Alfentanil (9737)..........................  II
Remifentanil (9739)........................  II
Sufentanil (9740)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for distribution to its customers.
    In reference to drug code 7360 (Marihuana), the company plans to 
bulk manufacture cannabidiol as a synthetic intermediate. This 
controlled substance will be further synthesized to bulk manufacture a 
synthetic THC (7370). No other activity for this drug code is 
authorized for this registration.
    Any other such applicant, and any person who is presently, 
registered with DEA to manufacture such substances may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than August 24, 2009.

    Dated: June 15, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator/Deputy Chief of Operation, Office of 
Diversion Control, Drug Enforcement Administration.
[FR Doc. E9-14697 Filed 6-22-09; 8:45 am]
BILLING CODE 4410-09-P